



## Investor Webinar

**24 July 2024**

**LTR Pharma Limited (ASX:LTP)** (“**LTR Pharma**”, “the **Company**”), a company focused on improving men’s health through the clinical development and commercialisation of an innovative nasal spray treatment for Erectile Dysfunction, SPONTAN®, is pleased to invite shareholders to a webinar on Thursday 25 July 2024 at 1:00pm AEST where Chairman, Lee Rodne, will provide a company update and engage in a Q&A session.

### LTP Investor Webinar Details

**Presenter:** Chairman, Lee Rodne

**Time:** Thursday 25 July 2024 at 1:00pm AEST

**Where:** Zoom Webinar, details to be provided upon registration. To register your interest for the webinar, please click through to the link below.

[https://janemorganmanagement-au.zoom.us/webinar/register/WN\\_-AeqcBFBQ22tUUg4lrF79g](https://janemorganmanagement-au.zoom.us/webinar/register/WN_-AeqcBFBQ22tUUg4lrF79g)

After registering, participants will receive a confirmation email with information about joining the webinar. Attendees will be able to submit questions via the panel throughout the presentation, and the Company encourages shareholders and investors to submit questions via email beforehand to [jm@janemorganmanagement.com.au](mailto:jm@janemorganmanagement.com.au)

– ENDS –

This announcement has been approved by the Board of Directors.

### About LTR Pharma

LTR Pharma is focused on improving men’s health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships across multiple age brackets. LTR Pharma’s lead product, SPONTAN®, is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body, supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

**For further information, please contact:**

**Haley Chartres**  
Media Relations  
[haley@hck.digital](mailto:haley@hck.digital)

**Peter McLennan**  
Investor Relations  
[investors@ltrpharma.com](mailto:investors@ltrpharma.com)